Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR Antibody + PD-1 Inhibitor + Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
ChiCTR2500106358Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nimotuzumab, gemcitabine and cisplatin in recurrent nasopharyngeal carcinoma (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: one-year progression-free survival (1y-PFS), Stage I: maximum tolerated dose (MTD) of nimotuzumab (if any) and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
nimotuzumabgemcitabinecisplatin
03
Conditions
recurrent nasopharyngeal carcinoma
Beyond the preview
Go deeper on ChiCTR2500106358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106358.